Company intelligence / Profile preview
Dongyangguang Pharmaceutical
Dongguan, Guangdong, Chinabloomberg.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Dongguan Dongyangguang Pharmaceutical has a pipeline focused on small molecules and hormones, targeting oncology, metabolic, and hematological diseases. Its most advanced asset, insulin aspart ("HEC"), for diabetes mellitus, has reached Phase 2 clinical trials. Other programs include multi-targeted kinase inhibitors for kidney neoplasms in Phase 1 and EGFR inhibitors for breast cancer in early development[2].
- Therapeutic areas
- EndocrinologyOncology
- Modalities
- Small moleculeHormone
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Dongyangguang Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dongyangguang Pharmaceutical.